|
Cohort1: AZD9150_Acalabrutinib
|
| Administration route |
intravenous infusion|oral |
| Dosage |
AZD9150, on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond)|Acalabrutinib, twice daily |
| Age |
Adult, Older_Adult |
|
|
Cohort2: Acalabrutinib_AZD6738
|
| Administration route |
intravenous infusion|oral |
| Dosage |
Acalabrutinib, twice daily|AZD6738, twice daily |
| Age |
Adult, Older_Adult |
|
|
Cohort3: Acalabrutinib_Hu5F9-G4_Rituximab
|
| Administration route |
intravenous infusion|oral |
| Dosage |
Acalabrutinib, twice daily|Hu5F9-G4, Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond|Rituximab, Weekly, on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8 |
| Age |
Adult, Older_Adult |
|
|
Cohort4: Acalabrutinib_AZD5153
|
| Administration route |
oral |
| Dosage |
Acalabrutinib, twice daily|once per day |
| Age |
Adult, Older_Adult |
|